Entos Pharmaceuticals develops next generation nucleic acid-based therapies using the proprietary Fusogenix proteo-lipid vehicle (PLV) drug delivery system. Fusogenix uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. Unlike conventional lipid-based delivery, Fusogenix is well tolerated at high systemic doses, and retains maximal activity with repeat dosing. Entos has developed unique formulations to effectively deliver a wide range of genetic therapies, including gene therapy, mRNA, miRNA, RNAi and CRISPR.

OncoSenX is a late stage pre-clinical cancer company. We target solid tumors based on transcriptional activity using a unique proteo-lipid vehicle gene therapy platform. The next generation in cancer therapies will be more targeted with less side effects. At OncoSenX we believe the battle against cancer should be fought with genetic information. Our treatment delivers a simple program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease.

Nanostics is a healthcare biotechnology company focused on development and commercialization of novel, non-invasive diagnostic tests. Our core technology is an advanced liquid biopsy platform that combines an advanced machine learning approach with extracellular vesicle analysis to accurately diagnose disease from a single drop of blood. Our lead product, ClarityDX Prostate, is the most accurate diagnostic test to diagnose aggressive prostate cancer, and is positioned to emerge as the world’s leading diagnostic tool for prostate cancer.

Oisín Biotechnologies is focused on technology that mitigates the effects of age-related diseases to address the damage created by the aging process itself. Our primary focus is killing senescent cells for the treatment and prevention of age-related diseases.

APCaRI is a multi-disciplinary team of over 300 prostate cancer scientists, physicians, patients, healthcare employees and an international collaborative network focused on clinical translation of innovative prostate cancer research from the laboratory to the clinic. APCaRI has 8 accruing trials open in 2020, including the Alberta Prostate Cancer Biorepository, a prospective study that has recruited more than 4000 patients and amassed over 300,000 biosamples connected with patient-reported and clinical outcomes, and the Alberta Prostate Cancer Registry, a continuously updated database of all Albertan prostate cancer patients linked with those in 14 countries through Movember’s TrueNTH Prostate Cancer Registry.